Deploying LLMs in Regulated Industries: The Eval Requirements You Can't Skip

When an ML team at a healthcare company or a financial institution asks us about LLM evaluation, the conversation quickly gets more specific than the usual "how do we catch hallucinations" framing. The question becomes: what evidence do we need to show auditors and compliance teams that our LLM-powered features behave within defined boundaries? What does "tested" mean in a context where the output can affect a patient's next care step or a customer's loan decision?

We're not going to tell you that running eval suites replaces a legal or compliance review — it doesn't. But we've worked through this with several growing teams deploying LLMs in regulated contexts, and there are specific eval criteria and eval process requirements that map directly to what compliance and legal teams ask for. Not having these in place is the most common reason LLM feature launches stall internally.

Why "it works in testing" isn't enough for regulated deployment

In unregulated B2B or consumer contexts, "it works in testing" often means "it produced reasonable outputs on the inputs I tried." For regulated contexts, that bar is inadequate because the downstream consequences of a bad output are documented, attributable, and potentially subject to legal or regulatory review.

Healthcare teams deploying LLMs in clinical documentation, patient communication, or care coordination features face expectations analogous to those in FDA guidance on software as a medical device (SaMD) — specifically, evidence that the system performs as intended across its stated use population, with documented testing that captures real-world edge cases. The EU AI Act establishes formal high-risk AI categories that explicitly include healthcare and financial services applications. These frameworks don't prescribe specific eval methods, but they create an expectation of documented, systematic quality testing — not ad hoc review.

For financial services, the relevant pressure comes from multiple directions: model risk management (MRM) frameworks like SR 11-7 from the Federal Reserve, which require model validation before deployment; fair lending concerns that require demographic performance consistency; and increasingly, CFPB and OCC guidance that flags AI-generated explanations for credit decisions as requiring accuracy and consistency standards.

The four eval criteria that map to compliance requirements

Consistency across equivalent inputs. In any regulated context, producing materially different outputs for inputs that should receive the same treatment raises fairness and reliability concerns. For a patient intake summarization feature, two patients with equivalent clinical presentations should receive equivalent summary quality. For a document review feature, the same legal language in two different documents should be interpreted consistently.

Eval criterion: run paraphrased or reformatted versions of the same underlying input through your feature and measure output consistency. Flag cases where the model produces materially different outputs for semantically equivalent inputs. This is distinct from measuring average quality — it measures reliability across equivalent inputs.

Demographic and subgroup performance consistency. Output quality should not vary systematically based on demographic signals in the input. For healthcare features that process patient notes, this means running your eval across notes that vary in patient demographic indicators and verifying that quality scores are consistent. For any feature where the input might encode demographic information — either explicitly or through proxies like language patterns or geographic references — this is a required eval dimension.

This is harder to implement than it sounds because you need an eval dataset with explicit demographic variation, which requires intentional dataset construction. The temptation to skip this because it's difficult is real. In our view, for regulated industry deployment, it's not optional.

Scope adherence and out-of-scope refusal. Regulated-context LLM features typically have a well-defined scope: a clinical documentation assistant is scoped to documentation support, not to providing clinical advice. A financial services chatbot is scoped to account management, not to investment recommendations. Outputs that exceed the defined scope — even if helpful in isolation — create liability.

Eval criterion: test your feature against a set of inputs designed to elicit out-of-scope responses. For each, verify that the model either refuses appropriately, redirects to in-scope handling, or flags the input for human review. The out-of-scope eval dataset should be built in collaboration with your legal or compliance team — they know which scope violations are high-risk.

Explainability and traceability. In financial services, a credit decision or product recommendation supported by an LLM needs to be explainable in terms a customer and an auditor can understand. "The model said so" is not an explanation. This creates an eval requirement: for features where the LLM output feeds into a consequential decision, you need eval coverage of whether the output includes reasoning that is accurate relative to the input data and traceable back to source material.

For RAG-based features, this maps to groundedness evaluation — does the output's reasoning stay within the retrieved source material? For non-RAG features, it maps to consistency between the stated reasoning and the conclusion. This is a harder evaluation problem, but it's non-negotiable for features where the output is used in decision-making contexts.

Eval process requirements, not just criteria

Compliance teams care about the process behind your eval, not just the scores. Specifically:

Documentation of the eval dataset and its construction. What inputs did you test? Who constructed the dataset? When? Was it updated to reflect changes in the feature or its use population? An undocumented eval dataset — even a good one — is difficult to defend in a compliance review. The dataset construction methodology and its evolution over time should be tracked explicitly.

Evidence that eval runs happened before releases. A log of "this eval was run on this date, against this feature version, and produced these scores, and these thresholds were met" is the minimum required evidence. For regulated contexts, this log needs to be persistent and auditable — not just visible in a dashboard that can be changed. In Fyntune's eval runs, every run is stored with a version hash of the prompt, the model endpoint, the eval dataset version, and the resulting scores. That record is immutable after creation. That's the kind of artifact a compliance review can use.

Evidence of human review on flagged outputs. Automated eval can establish that a feature's quality was within defined thresholds. It cannot, by itself, replace human review of edge cases and high-stakes outputs. For regulated contexts, the eval process should include a defined trigger for human review — for example, any output that scores below threshold on a critical criterion, or any output from a specific high-risk input category, gets reviewed by a qualified human before that output pattern is approved for production. Document who reviewed it and when.

What we'd tell a team about to launch a healthcare LLM feature

Before going to your compliance team with a production launch request, have these in place:

• An eval dataset that explicitly covers edge cases, demographic variation, and out-of-scope inputs — with documented construction methodology.
• Eval criteria that include consistency across equivalent inputs, demographic performance consistency, and scope adherence — not just generic quality metrics.
• An immutable eval run log that shows the feature met defined thresholds prior to each release.
• A documented process for human review of flagged outputs, with evidence that it was followed.
• A regression testing cadence: not just pre-launch eval, but ongoing eval on a defined schedule, with a defined process for what happens if scores degrade post-launch.

We're not suggesting this list is sufficient for every regulated context — healthcare HL7 FHIR-based data workflows, financial services SR 11-7 model validation requirements, and legal document AI each have specific requirements beyond generic LLM quality eval. But this list covers the baseline that most compliance teams expect before they'll approve a production LLM feature, regardless of vertical.

The teams that get stuck in compliance review are almost always missing documentation, not quality. The feature works fine; they just have no systematic evidence that it works fine, and no process evidence that they'll know if it stops working fine. That's the gap that rigorous eval infrastructure closes — and it's a gap that's much cheaper to close before your compliance review than after.